

Economic Evaluation of disease modifying treatments in patients with relapsing remitting Multiple Sclerosis in Germany: long term analysis and cost effectiveness of Natalizumab, interferon-beta and glatiramer acetate

N. Putzki^{1,2}, D. Eheberg³, A. Bergmann⁴, M. Lang⁴, C. Plesnila-Frank³, V. Limmroth⁵, Z. Katsarava¹

¹ Abteilung für Neurologie, Universitätsklinikum Essen; ² Klinik für Neurologie, Kantonsspital St. Gallen; ³ IMS HEOR, IMS Health GmbH & Co. OHG, München; ⁴ NTD-studygroup, NeuroTransData GmbH, Neuburg; ⁵ Neurologische Klinik, Kliniken der Stadt Köln

Background

- Multiple sclerosis (MS) affects approximately 120 000 patients in Germany¹.
- Within the last decades different disease modifying therapies (DMT) have proven their benefits for patients with relapsing remitting multiple sclerosis (RRMS)²⁻⁴ but these DMTs come at high costs⁷.

Objective

- To conduct a health economic evaluation of Natalizumab (Nb) compared to other disease modifying drugs (DMD) in RRMS patients based on literature and German real-life treatment data.

Method

Decision-analytic model:

- A Microsoft Excel™-based Markov model was constructed to compare the costs and outcomes of Natalizumab (Nb), Interferon-beta (INF-b), glatiramer acetate (GA) and best supportive care (BSC).

Model Framework & Patient cohort

Model Type	Markov, stage-transition model
Time horizon	30 years
Cycle length	3 months
Perspective	Societal perspective
Patient starting age	35 years
Gender distribution	72.50% females, 27.50% males
Annual discount rate	3%

- Clinical Trials and published literature were used to derive the model parameter:
 - Efficacy and withdrawal rates were derived from trials⁴ (Nb) or published meta analysis^{2,3,5,6} (INF-b and GA).
 - Costs and utilities were taken from a published retrospective analysis of cost associated with MS in Germany⁷.
 - Side effects inclusive progressive multifocal leukoencephalopathy (PML) are reflected in costs and utilities.
- An univariate sensitivity analysis of multiple model parameters was performed




Figure 1: Model structure

Method (cont.)

- The mutually exclusive Markov states are defined by the Expanded Disability Status Scale (EDSS) stages and the course of treatment (Figure 1).
- The model transitions are defined by disease progression. Patients can switch medication or withdraw from treatment at all within each cycle.
- Cost-effectiveness was measured as incremental cost per relapse avoided and per quality-adjusted life-year (QALYs) gained.

Assumptions:

- In each cycle patients can stay at their current EDSS state or move to the next state.
- Transition between RRMS and secondary progressive MS occurs at state EDSS 7.
- Relapse: Only one per cycle; constant risk for relapse in EDSS state 1 to 6; no relapses in EDSS 7 to 9.

German real-life data collection:

- A real-life data collection was conducted in 2010 to evaluate model parameters and to validate model assumptions.
- Data from 554 patients treated with DMTs for RRMS within the last 2 years were collected retrospectively.
- Data sources: Universitätsklinikum Essen, Neurologische Klinik Köln, Kantonsspital St. Gallen and NeuroTransData (one large network of office based neurologists).

Method (cont.)

Inclusion criteria

Age	> 18
Diagnosis	RRMS
EDSS Score	< 6
Course of treatment	Nb, INF-b or GA
Treatment switches	< 2 treatment switches
Treatment history	At least treated for 2 years in one center

Results of real life data collection

- Overall real life data supported the model assumptions.
- Risk for progression and relapse were constant for all EDSS stages.
- After 12 months no mean progression could be detected. (-0.07; CI -0.13 - -0.01). A possible explanation for the minimal overall improvement is the recovery from prior relapses.

DMT [95% CI]	N	Initial EDSS	Relapse rate
Nb	153	3.46 [3.21-3.72]	0.23 [0.14-0.33]
INF-b	196	1.32 [1.21-1.51]	0.44 [0.33-0.56]
GA	205	1.73 [1.53-1.93]	0.46 [0.34-0.57]
Total	554	2.12 [1.97-2.27]	0.39 [0.33-0.45]

All values reported as mean [95% CI]

Results of model

- Model results indicate that patients managed by best supportive care experience an average 15 relapses within 30 years.




Figure 2: Avoided relapses per patient

Results of model (cont.)

1st line	2nd line	Costs [€]	QALY	Cost per QALY [€]
Nb	Other DMT	835,972	14.04	59,532
Other DMT	Nb	795,458	12.96	61,361
BSC		581,201	12.20	47,647

- The incremental cost-effectiveness (ICER) of Nb versus other DMT is € 37,552 per QALY.
- The patient distribution after 30 years suggests a slower progression for patients under DMT.




Figure 3: Patient distribution after 30 years

- According to the sensitivity analysis the model is most sensitive to parameter related to the progression.
- The ICER of Nb is € 33,664 per QALY using real life data as an alternative setting.

Conclusion

- Treatment with DMT improves the situation of patients, with Nb showing the highest efficacy and best cost-effectiveness ratio.
- The ICER suggests that the additional cost per QALY are in an acceptable range with € 37,552.

References

- Hein T, Hopfenmuller W. Projection of the number of multiple sclerosis patients in Germany. *Nervenarzt* 2000;71(4):288-294.
- Cadavid D, Wolansky LJ, Skurnick J et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. *Neurology* 2009;72(23):1976-1983.
- O'Connor P, Filippi M, Arnason B et al. 250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. *Lancet Neurol* 2009;8(10):889-897.
- Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med* 2006;354(9):899-910.
- Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. *N Engl J Med* 2000;343(20):1430-1438.
- Rice GP, Incurva B, Munari L et al. Interferon in relapsing-remitting multiple sclerosis. *Cochrane Database Syst Rev* 2001;(4):CD002002.
- Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. *J Neurol Neurosurg Psychiatry* 2006;77(8):918-926.